Eradication of FIX inhibitor in haemophilia B children using low‐dose immune tolerance induction with rituximab‐based immunosuppressive agent(s) in China-Reference-Cited by-同舟云学术

Eradication of FIX inhibitor in haemophilia B children using low‐dose immune tolerance induction with rituximab‐based immunosuppressive agent(s) in China

Published:2022-05-03 Issue:4 Volume:28 Page:625-632
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Li Zekun¹²^ORCID,Liu Guoqing¹,Yao Wanru¹,Chen Zhenping²^ORCID,Li Gang²,Cheng Xiaoling³^ORCID,Zhen Yingzi¹,Ai Di¹²^ORCID,Huang Kun¹²^ORCID,Sun Jie¹²^ORCID,Poon Man‐Chiu⁴⁵⁶⁷^ORCID,Wu Runhui¹^ORCID

Affiliation:

1. Haemophilia Comprehensive Care Center, Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology; Key Laboratory of Major Diseases in Children, Ministry of Education, National Center for Children's Health National Key Discipline of Pediatrics (Capital Medical University), Beijing Children's Hospital, Capital Medical University Beijing China

2. Haematologic Disease Laboratory, Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology; Key Laboratory of Major Diseases in Children, Ministry of Education; Beijing Pediatric Research Institute, National Center for Children's Health National Key Discipline of Pediatrics (Capital Medical University), Beijing Children's Hospital, Capital Medical University Beijing China

3. Pharmacology Department, National Center for Children's Health Beijing Children's Hospital, Capital Medical University Beijing China

4. Department of Medicine University of Calgary Cumming School of Medicine Calgary Alberta Canada

5. Department of Pediatrics University of Calgary Cumming School of Medicine Calgary Alberta Canada

6. Department of Oncology University of Calgary Cumming School of Medicine Calgary Alberta Canada

7. Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program Foothills Hospital, Alberta Health Services Calgary Alberta Canada

Funder

Beijing Municipal Science and Technology Commission

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14577

Reference38 articles.

1. Inhibitor development in haemophilia B: an orphan disease in need of attention

2. Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study

3. Haemophilias A and B

4. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition)

5. WFH Guidelines for the Management of Hemophilia, 3rd edition

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. F9 mutations causing deletions beyond the serine protease domain confer higher risk for inhibitor development in hemophilia B;Blood;2023-02-09

2. Immunosuppressants/prothrombin-complex-concentrate;Reactions Weekly;2022-10-29

3. Factor IX inhibitors in haemophilia B: A report of National Haemophilia Registry in China;Haemophilia;2022-09-26